Literature DB >> 6813491

Auranofin and lysosomal enzymes.

A E Finkelstein, F R Roisman, M G Ladizesky, D T Walz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6813491

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN： 0380-0903


× No keyword cloud information.
  5 in total

1.  Auranofin modulates mast cell histamine and polymorphonuclear leukocyte collagenase release.

Authors:  E Wojtecka-Lukasik; I Sopata; S Maśliński
Journal:  Agents Actions       Date:  1986-04

Review 2.  Current status of disease-modifying drugs in progressive rheumatoid arthritis.

Authors:  J D O'Duffy; H S Luthra
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

3.  Effects of anti-rheumatic gold salts on NF-kappa B mobilization and tumour necrosis factor-alpha (TNF-alpha)-induced neutrophil-dependent cytotoxicity for human endothelial cells.

Authors:  J Bratt; J Belcher; G M Vercellotti; J Palmblad
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

Review 4.  Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis.

Authors:  M Chaffman; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

5.  Effect of two gold compounds on lysosomes.

Authors:  P M Graabaek; S M Pedersen
Journal:  Ann Rheum Dis       Date:  1988-06       Impact factor: 19.103
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.